Ajinomoto BioPharma Services
Senior Partner
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on… Read More
Heidelberg Pharma
Senior Partner
Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
Mersana
Senior Partner
Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Utilizing our technology, we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies.
ImmunoGen
Senior Partner & Awards Sponsor
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company’s lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen’s ADC technology to develop anticancer therapies; it is used in Roche’s marketed product, Kadcyla.
Seattle Genetics
Senior Partner
Seattle Genetics improves the lives of people with cancer through innovative and empowered antibody-based therapies. ADCETRIS(r) (brentuximab vedotin), the company’s lead product, is the first in a new class of ADCs for relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors, including vadastuximab talirine, an ADC in a phase 3 trial for acute myeloid leukemia.
AbbVie
Headline Awards Sponsor
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Abmart
Program Partner
Multitude Therapeutics (MTX) is a preclinical-stage business unit created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy.MTX focuses on developing novel antibody-drug conjugates (ADC) and immuno-oncology (I/O) (T cells and macrophages) based antibody therapeutics for solid and blood tumors… Read More
Ambrx
Awards Sponsor
Ambrx®, Inc. is a clinical stage biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx® technology combines site-specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties… Read more
Goodwin Biotechnology
Spotlight Partner
Goodwin Biotechnology, Inc. (GBI) is a biological contract development and manufacturing organization (CDMO) and a Single Source Solution™ provider offering process development and cGMP contract manufacturing services for mammalian cell culture-derived biologics including vaccines, monoclonal antibodies, and recombinant proteins. One of our key capabilities is Bioconjugation to generate Antibody Drug Conjugates (ADCs and CADCs), Radio-Immunoconjugates… Read More.
